TRK-950 is under clinical development by Toray Industries and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how TRK-950’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

TRK-950 overview

TRK-950 is under development for the treatment of advanced or metastatic solid carcinomas, metastatic colon cancer, metastatic cholangiocarcinoma, metastatic colon cancer, metastatic gastric cancer, colorectal cancer, metastatic ovarian cancer, renal cell carcinoma, gastroesophageal junction cancer, melanoma, epithelial ovarian, primary peritoneal or fallopian tube cancer and metastatic bladder cancer. The drug candidate is administered through intravenous route. It is a monoclonal antibody that acts by targeting undisclosed tumor-associated antigen (TAA). It was also under development for the treatment for hepatomas. 

Toray Industries overview

Toray Industries (Toray) is a provider of advanced materials. The company’s product portfolio includes fibers, fashion apparel, plastics, chemicals, composite materials, life sciences products, and medical devices, pharmaceuticals, and optical products. It also provides carbon fibers, carbon fiber composite materials, polyester, polyethylene, polypropylene and water treatment membranes. Its products are used in apparel, industrial materials, automotive, construction, water treatment and medical industries. It also provides physical evaluation, analysis, and research related services. Toray also provides comprehensive engineering, condominiums, industrial equipment and machinery, IT-related equipment, water treatment membranes and related equipment, materials for housing, building and civil engineering applications. The company operates in various countries in Asia Pacific, North America, South America and Europe. Toray is headquartered in Tokyo, Japan.

For a complete picture of TRK-950’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.